Qiagen reported after the close of the market on Tuesday that its fourth quarter revenues grew 2 percent year over year, beating previous guidance and analyst estimates on the top and bottom line.

DNA sequencing firm Element Biosciences said on Tuesday that it has acquired Loop Genomics for an undisclosed amount.

On January 29, Shenzhen Tisenc Medical Devices Co., Ltd. underwent an industrial and commercial change. All the original shareholders withdrew, and WONDFO BIOTECH (300482) was newly added, holding 100% of the shares.

Hologic reported after the close of the market on Wednesday that revenues for its first quarter of fiscal year 2022 decreased 9 percent year over year, driven by lower sales of COVID-19 assays.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has approved the planned spinoff of its diabetes care business, which will be known as Embecta Corp.

The “COVID-19 Antigen Rapid Test – Anterior Nasal Swab” and the “COVID-19 Antigen Rapid Test (Colloidal Gold) – Saliva” developed independently by JOINSTAR Biomedical Technology Co., Ltd obtained the EU CE certification for self-testing on January 20th and February 2nd, issued by the CE 1434.

Becton Dickinson said on Tuesday that it has acquired Cytognos, a privately held developer of flow cytometry-based tests for hematologic cancer and blood diseases, from its parent firm Vitros.

Medix Biochemica has acquired 100 percent of the shares of myPOLS Biotec GmbH, a German manufacturer of innovative and high-quality raw materials in molecular diagnostics.

Thermo Fisher Scientific on Wednesday morning reported a 1 percent increase in fourth quarter revenues and a 22 percent rise in full-year 2021 revenues. The company also raised its revenue and earnings guidance for 2022.

Two researchers from Skoltech and McGill University have published a review of the promising research field known as structural proteomics in the influential journal Chemical Reviews.

Danaher reported on Thursday a 21 percent year-over-year increase in total sales for the fourth quarter, beating the consensus Wall Street estimate. For the three months ended Dec. 31, conglomerate posted $8.15 billion in total sales compared to $6.76 billion in the year-ago period. The analysts' average estimate was $7.92 billion.

iHealth announced that it was disclosed in the previous announcement that the U.S. subsidiary of the company and the ACC of U.S. signed a purchase contract on ihealth coronavirus antigen home self-test OTC kit products on behalf of HHS, purchasing a total of 250 million iHealth kit products.

VIEW has been indexed in Chemical Abstracts Service (CAS) and Information Service for the Physics, Electro-technology, Computer and Control (INSPEC).

Abbott reported Wednesday morning that its fourth quarter diagnostics revenues rose 3 percent year over year, largely as a result of rapid COVID-19 testing.

GE's healthcare systems organic revenues in the fourth quarter declined 5%, more than offsetting 2% organic growth in pharmaceutical diagnostics. Nonetheless, Culp told investors that healthcare order demand remained strong in the quarter despite supply chain disruptions.